Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III dose-optimization study of lisdexamfetamine in children and adolescents with ADHD
2008-000679-90Phase 3Completed
- Sponsor
- Takeda
- Start
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lisdexamfetamine in attention deficit hyperactivity disorder (ADHD) (3 arms), sponsored by Takeda. Primary endpoint: Change from baseline in ADHD-RS-IV total score at endpoint. Started May 2008; status: completed.
02
Drugs
lisdexamfetamine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on 2008-000679-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000679-90.